• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MetLife (MET) Valuation Check After Fresh Dividend Declaration And Steady Long Term Returns

    Simply Wall St·01/07/2026 16:21:38
    Listen to the news

    Dividend affirmation puts MetLife in focus for income investors

    MetLife (MET) is back on income investors’ radar after its board declared a first quarter 2026 common stock dividend of US$0.5675 per share, payable on March 10 to shareholders of record on February 3.

    See our latest analysis for MetLife.

    Recent trading has been relatively steady, with a 30 day share price return of 3.20% and a year to date share price return of 1.07%. The 5 year total shareholder return of 88.64% points to stronger longer term compounding and suggests momentum has built over multi year periods rather than in the very short term. Short interest has also eased, and with the fresh dividend affirmation, this combination may be influencing how investors view MetLife’s income profile and risk today.

    If this kind of income story has your attention, it could be a good time to look across other healthcare stocks for different risk and dividend profiles. See how they compare on quality and stability.

    With MetLife reporting annual revenue of US$71.9b, net income of US$3.6b and the shares trading around US$81.18, the key question now is whether that income stream is undervalued or if the market is already pricing in future growth.

    Most Popular Narrative: 12.6% Undervalued

    With MetLife last closing at US$81.18 against a narrative fair value of about US$92.93, the current pricing sits below that valuation anchor.

    Strategic expansion of asset-light, fee-generating businesses (such as employee benefits, asset management, and longevity reinsurance), combined with disciplined capital management, supports higher return on equity and more consistent, less capital-intensive earnings growth.

    Read the complete narrative.

    Curious what earnings path and margin profile justify that gap to fair value, and how retirement income products fit into the story? The narrative spells out specific revenue glidepaths, profit margin assumptions and a future earnings multiple that together underpin this valuation call.

    Result: Fair Value of $92.93 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still real pressure points to watch, including interest rate and investment income swings that could squeeze margins, and credit losses on commercial mortgage loans affecting earnings and capital.

    Find out about the key risks to this MetLife narrative.

    Build Your Own MetLife Narrative

    If you see the numbers differently or simply prefer to test your own assumptions, you can build a custom MetLife story in minutes: Do it your way.

    A great starting point for your MetLife research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Looking for more investment ideas?

    If MetLife has sharpened your focus on income and value, do not stop here. Use the screener to quickly surface other stocks that match your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.